Overview

Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).

Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Atezolizumab in patients with urinary tract squamous cell carcinoma: a single-arm, open-label, multicentre, phase II clinical trial
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Southampton NHS Foundation Trust
Collaborators:
Cancer Research UK
Roche Pharma AG
Treatments:
Atezolizumab